Samsung Medical Center

The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem Report 2023-2030: Global Opportunities, Challenges, Strategies & Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024

The "The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem 2023-2030: Opportunities, Challenges, Strategies & Forecasts" report from SNS Telecom & IT has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem 2023-2030: Opportunities, Challenges, Strategies & Forecasts" report from SNS Telecom & IT has been added to ResearchAndMarkets.com's offering.
  • The report estimates that global investments in 5G NR and LTE-based RAN (Radio Access Network) infrastructure operating in shared and unlicensed spectrum will account for more than $1.4 Billion by the end of 2023.
  • The report also provides global and regional forecasts for shared and unlicensed spectrum LTE/5G RAN infrastructure from 2023 to 2030.
  • The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Monday, December 11, 2023

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023

SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Monday, November 13, 2023

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

Retrieved on: 
Wednesday, November 1, 2023

The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.

Key Points: 
  • The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.
  • Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment.
  • Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME.
  • Visit Lunit's booth at SITC 2023 at Booth #227 to learn more about these pioneering studies.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023

Retrieved on: 
Monday, October 23, 2023

ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain on October 23rd, 2023.

Key Points: 
  • ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain on October 23rd, 2023.
  • The dose-escalation study aimed to assess the safety and tolerability, and to establish the recommended Phase 2 dose (RP2D) of IMC-002.
  • 92% of treatment-related adverse events (TRAE) were of Grade 1-2, with 94% occurring during the first treatment cycle.
  • In addition to the CD47 antibody IMC-002, ImmuneOncia also has a wide range of pipeline that includes the Phase 2 clinical-stage PD-L1 antibody IMC-001, and the preclinical-stage bispecific antibody IMC-201.

Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Monday, September 11, 2023

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced follow-up results from the Phase 1b/2 CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations. These findings are being presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Congress on Lung Cancer (WCLC) from September 9-12 in Singapore.1

Key Points: 
  • Resistance in patients is typically diverse and polyclonal, meaning their tumors can have more than one type of resistance caused by different pathways.
  • Results from the RYBREVANT®, lazertinib and chemotherapy combination cohort (n=20), were featured in a mini oral presentation ( Abstract #MA13.06 ) at the IASLC 2023 WCLC.
  • Five patients were treated beyond progression, with a median incremental treatment duration of 4.2 months.
  • "These results provide important insights into the treatment of patients with advanced non-small cell lung cancer with EGFR-mutated disease who have progressed on the current standard of care.

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

Retrieved on: 
Wednesday, June 14, 2023

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

Key Points: 
  • SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
  • This product is a companion diagnostic test designed to detect EGFR mutations commonly found in NSCLC patients and guide the selection of appropriate targeted anticancer therapies based on the test results.
  • Compared to existing EGFR mutation tests using RT-PCR, this product demonstrates significantly higher sensitivity.
  • This is the second EGFR mutation test for which Gencurix has obtained approval.

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

Retrieved on: 
Friday, June 9, 2023

An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.

Key Points: 
  • An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.
  • Associated with the AFM13-induced cytotoxic activity was an increased functional activation status of AB-101 demonstrated through degranulation and IFN-γ production.
  • Importantly, in a mouse xenograft model, adoptive transfer of AB-101 in combination with AFM13 conferred tumor growth control.
  • The data of AFM13 in combination with the allogeneic, cryopreserved, off-the-shelf, cord blood-derived AB-101 NK cells demonstrate synergistic anti-tumor activity in vivo.